Cost-Effectiveness of Left Ventricular Assist Devices (LVADs) as Permanent Implants for End-Stage Heart Failure David Samson Blue Cross and Blue Shield.

Slides:



Advertisements
Similar presentations
Trend for Precision Soil Testing % Zone or Grid Samples Tested compared to Total Samples.
Advertisements

Trend for Precision Soil Testing % Zone or Grid Samples Tested compared to Total Samples.
Background images courtesy of abc.com 1,000, , , ,000 64,000 32,000 16,000 8,000 4,000 2,000 1,
AGVISE Laboratories %Zone or Grid Samples – Northwood laboratory
Trend for Precision Soil Testing % Zone or Grid Samples Tested compared to Total Samples.
Chemical Quantities or
Figure 2 Projected Total Costs During Bridging Period LOWER COSTS ASSOCIATED WITH HOME DISCHARGE OF BRIDGE-TO-TRANSPLANT PATIENTS USING THE TLC-II PORTABLE.
Fill in missing numbers or operations
1
EuroCondens SGB E.
Copyright © 2003 Pearson Education, Inc. Slide 1 Computer Systems Organization & Architecture Chapters 8-12 John D. Carpinelli.
Sequential Logic Design
1 Copyright © 2013 Elsevier Inc. All rights reserved. Appendix 01.
Electricity and Natural Gas Supply, Reserves, and Resource Adequacy CMTA Energy Conference Energy: Growing Californias Economy William J. Keese California.
Properties Use, share, or modify this drill on mathematic properties. There is too much material for a single class, so you’ll have to select for your.
OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.
ISHLT/MCSD Analysis: Jan 2002 – Dec 2004, n= Deaths * censored at transplant Percent Survival Months after Device Implant Deaths / Month Event:
ISHLT/MCSD Analysis: Jan 2002 – Dec 2004, n= Deaths * censored at transplant Percent Survival Months after Device Implant Deaths / Month Event:
2004 ISHLT J Heart Lung Transplant 2004; 23: HEART TRANSPLANTATION Pediatric Recipients.
Performance of Hedges & Long Futures Positions in CBOT Corn Goodland, Kansas March 2, 2009 Daniel OBrien, Extension Ag Economist K-State Research and Extension.
CALENDAR.
CHAPTER 18 The Ankle and Lower Leg
Who Wants To Be A Millionaire?
Who Wants To Be A Millionaire? Decimal Edition Question 1.
£1 Million £500,000 £250,000 £125,000 £64,000 £32,000 £16,000 £8,000 £4,000 £2,000 £1,000 £500 £300 £200 £100 Welcome.
The 5S numbers game..
1 A B C
A Fractional Order (Proportional and Derivative) Motion Controller Design for A Class of Second-order Systems Center for Self-Organizing Intelligent.
Sampling in Marketing Research
Break Time Remaining 10:00.
The basics for simulations
EU Market Situation for Eggs and Poultry Management Committee 21 June 2012.
1 Slides revised The overwhelming majority of samples of n from a population of N can stand-in for the population.
1 Prediction of electrical energy by photovoltaic devices in urban situations By. R.C. Ott July 2011.
Surgical Intervention Including Devices Victor F Garcia MD.
Copyright © 2012, Elsevier Inc. All rights Reserved. 1 Chapter 7 Modeling Structure with Blocks.
1 RA III - Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Buenos Aires, Argentina, 25 – 27 October 2006 Status of observing programmes in RA.
Solutions to Section 7.1. Prob#Billing Date Previous Balance Finance Charge New Purchases Payments Credits New Balance 38/15$ 600$ 9$ 140$ 100$ /22$
We are learning how to read the 24 hour clock
1..
1 Core Segments: Price Value Shoppers : Very much focused on getting the best value for their money, Price Value Shoppers love to shop, and take pride.
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
MaK_Full ahead loaded 1 Alarm Page Directory (F11)
TCCI Barometer September “Establishing a reliable tool for monitoring the financial, business and social activity in the Prefecture of Thessaloniki”
When you see… Find the zeros You think….
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Before Between After.
10/23/2003 Copyright Ossur Össur hf. Q /23/2003 Copyright Ossur Key ratios YTD 2003 / % +6% -15%-19%- 23%
 Find the difference between the two numbers on the red boxes.  If the difference of the red boxes matches the blue box say “deal” f not, it’s “no.
2.10% more children born Die 0.2 years sooner Spend 95.53% less money on health care No class divide 60.84% less electricity 84.40% less oil.
: 3 00.
5 minutes.
Weisburd, Lawton, Ready, Rudes, Cave, and Nelson Presented by Breanne Cave 1.
Essential Cell Biology
Converting a Fraction to %
New Lesions versus Growth of Existing Disease: Does it impact prognosis? Axel Grothey¹, James Heun¹, Megan Branda¹, Richard M. Goldberg², Dan Sargent¹.
Resistência dos Materiais, 5ª ed.
Clock will move after 1 minute
Partial Products. Category 1 1 x 3-digit problems.
PSSA Preparation.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.
Immunobiology: The Immune System in Health & Disease Sixth Edition
Select a time to count down from the clock above
Murach’s OS/390 and z/OS JCLChapter 16, Slide 1 © 2002, Mike Murach & Associates, Inc.
Schutzvermerk nach DIN 34 beachten 05/04/15 Seite 1 Training EPAM and CANopen Basic Solution: Password * * Level 1 Level 2 * Level 3 Password2 IP-Adr.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.
Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,
Presentation transcript:

Cost-Effectiveness of Left Ventricular Assist Devices (LVADs) as Permanent Implants for End-Stage Heart Failure David Samson Blue Cross and Blue Shield Association Technology Evaluation Center, University at Albany Thanks to:Alan M. Garber Stanford University Gillian Sanders Duke University Naomi Aronson Blue Cross and Blue Shield Association Technology Evaluation Center Copyright 2004 Blue Cross Blue Shield Association

Rose et al. NEJM, 2001; 345:1435

REMATCH Trial REMATCH: destination therapy, in contrast to bridge to transplant 129 patients with NYHA Class IV end-stage heart failure, contraindications for heart transplantation, randomized to LVAD or optimal medical management (OMM) Median survival: LVAD d, OMM d ( 8.5 mo, p=0.001) Rate of all serious adverse events per patient-yr: LVAD , OMM , rate ratio (95% CI): 2.35 ( ) Copyright 2004 Blue Cross Blue Shield Association

REMATCH Trial Copyright 2004 Blue Cross Blue Shield Association CDRH- FDA, CSDAP, 03/04/02

REMATCH Trial 1 yr median NYHA Class: LVAD - II, OMM - IV (p<0.001) 1 yr mean SF-36 PF: LVAD - 46, OMM - 21 (p=0.01) Copyright 2004 Blue Cross Blue Shield Association Class I: No limitation on physical activity (sx > ordinary activity) Class II: Slight limitation on physical activity (sx ordinary activity) Class III: Marked limitation on physical activity (sx < ordinary activity) Class IV: Inability to carry on physical activity (sx at rest)

REMATCH Trial Copyright 2004 Blue Cross Blue Shield Association Thoratec, FDA, CSDAP, 03/04/02

Structural Components of CEA Time horizon, perspective:Lifetime (3 years), payor Patient population, setting:REMATCH patient selection, sites Strategies:LVAD, OMM Markov model: 2-state (analogous to 3-state) Quality of life focus:NYHA functional class categories Valuing of Costs:2002 $ US Copyright 2004 Blue Cross Blue Shield Association

Markov Model Copyright 2004 Blue Cross Blue Shield Association AliveDead p 11 1 NYHA III/IV p 11 p 22 Dead NYHA I/II p 12 p 13 p 23 1 p 21 2-State: 3-State:

Cycle-Specific Calculation of QALYs, Costs QALY t = S t [(P I/II *U I/II )+(P III/IV *U III/IV )] t /12 C t = S t [(P rehosp *C rehosp )+(P outpt *C outpt )] Copyright 2004 Blue Cross Blue Shield Association t = monthly cycle S t = survival probability P I/II, P III/IV = probability of being in NYHA class categories U I/II, U III/IV = utility of being in NYHA class categories P rehosp, P outpt = probability of being rehospitalized, outpatient C rehosp, C outpt = cost of being rehospitalized, outpatient

Parameter Estimates Survival, LVAD:OMMHR=0.5295% CI: 0.34, 0.78 Survival extrapolationinterpolationstop & drop, 2 sets to 3 yr parametric models NYHA I/II utility NYHA III/IV utility Copyright 2004 Blue Cross Blue Shield Association

Parameter Estimates LVAD P rehosp OMM P rehosp LVAD C implant $277,001$125K - $425K LVAD/OMM C rehosp $39,896$10K - $70K LVAD/OMM C outpt $1,719$250 - $3,250 Discount, costs/utilities3%1% - 5% Copyright 2004 Blue Cross Blue Shield Association

Results: Baseline, Sensitivity Analysis on Survival Relation Copyright 2004 Blue Cross Blue Shield Association

Sensitivity Analysis on Survival Extrapolation Copyright 2004 Blue Cross Blue Shield Association

Sensitivity Analysis on Cost of Implantation Copyright 2004 Blue Cross Blue Shield Association

Sensitivity Analysis on Cost of Implantation Copyright 2004 Blue Cross Blue Shield Association

Sensitivity Analysis on NYHA Utilities Copyright 2004 Blue Cross Blue Shield Association

Sensitivity Analysis on NYHA Utilities Copyright 2004 Blue Cross Blue Shield Association

Sensitivity Analysis on NYHA Utilities Copyright 2004 Blue Cross Blue Shield Association

Sensitivity Analysis on Rehospitalization/Outpatient Costs Copyright 2004 Blue Cross Blue Shield Association

Sensitivity Analysis on Probability of Rehospitalization Copyright 2004 Blue Cross Blue Shield Association

Sensitivity Analysis on Discount Rate Copyright 2004 Blue Cross Blue Shield Association

Conclusions CEA results most sensitive to cost of LVAD implantation In 1-way and 2-way sensitivity analyses, ICERs < $500K/QALY depended on unrealistic assumptions, especially about cost of LVAD implantation Destination LVADs exceed common CE standards Results raise questions of resource use for end-of-life care Copyright 2004 Blue Cross Blue Shield Association

References CDRH-FDA. Presentation to FDA-CSDAP, March 4, Frazier et al. Ann Surg, 1995;222(3): Frazier et al. Ann Thorac Surg, 1994;57: Gelijns et al. Ann Thorac Surg, 1997;64: Moskowitz et al. Ann Thorac Surg, 2001;71:S Moskowitz et al. Ann Thorac Surg, 1997;64: Oz et al. Ann Surg, 2003;238(4): Rose et al. N Engl J Med, 2001;345(20): Samson. TEC, 2004;19(2):1-36 (bcbs.com/tec/vol19/19_02.html) Thoratec. Presentation to FDA-CSDAP, March 4, Copyright 2004 Blue Cross Blue Shield Association